New Upstream Dual Listing: Global Compliance Applications Corporation
Global Compliance Applications Corporation is now available on Upstream under the ticker symbol ‘GCAC’.
The dual listing on Upstream is designed to provide GCAC the opportunity to access a global investor base outside the U.S., unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in the company.
Traders on Upstream’s smart contract-powered platform will experience real-time trading and settlement, and a transparent orderbook which does not permit common market manipulations. Note, U.S. persons may not deposit, buy or sell securities on Upstream.
Details on the GCAC listing and deposit and trading instructions can be found at https://upstream.exchange/gcac.
Get to know GCAC:
For the Upstream community who may not know you yet, please give a short intro on who your company is?
GCAC is a global leader in blockchain and machine learning solutions, with its patented Efixii Uplift platform, an Ethereum Layer 2 blockchain. GCAC was awarded a groundbreaking approved patent application for using blockchain to determine the medical efficacy of cannabis—a first in the industry. Through Uplift, GCAC connects producers, distributors, and retailers, enhancing consumer experiences and sales via blockchain-verified digital coupons for cannabis and CBD. GCAC also offers cost-effective SaaS blockchain solutions for various agricultural industries, adding value and transparency across supply chains.
What’s one or two of your biggest initiatives this year as a company?
One of GCAC’s biggest initiatives this year is expanding the Efixii Uplift platform, which leverages our patented blockchain technology to verify the medical efficacy of cannabis. This breakthrough allows us to provide blockchain-verified digital coupons for cannabis and CBD, connecting dispensaries and brands directly with veterans and other consumers. Another key focus is growing our presence on Citizen Green TV (CGTV), the only dedicated veteran health & wellness streaming channel, where dispensaries can advertise legally and integrate Uplift coupons to reach a large, loyal audience.
What’s a recent trend in your industry that you believe sets up your company for success?
A key trend driving our success is the growing shift towards non-opioid treatments, especially among veterans and patients seeking alternatives for pain management and PTSD relief. As cannabis legalization expands across the USA, there’s a rising demand for consistent, high-quality cannabis products. This aligns with GCAC’s mission, as our Efixii Uplift platform uses blockchain to ensure transparency and verify the medical efficacy of cannabis. Our technology helps brands and dispensaries maintain product integrity, while also providing consumers with blockchain-verified cannabis and CBD products, meeting the demand for both safety and quality assurance.
Why should shareholders be excited about the dual listing with Upstream?
GCAC’s dual listing with Upstream opens the door to global investors, particularly in Europe and Asia, where blockchain technology is widely integrated into industries like healthcare, supply chain management, and legal compliance. Upstream’s blockchain-powered securities exchange allows GCAC to showcase Efixii’s patented technology to markets that prioritize transparency and long-term utility, aligning perfectly with regions that emphasize regulatory compliance and data integrity.
Where can shareholders learn more about your dual listing and how to participate in digital rewards?
Company Website: https://globalcompliance.app/
Upstream profile page: https://upstream.exchange/gcac
Disclaimers:
U.S. persons may not deposit, buy or sell securities on Upstream.
This communication does not constitute an offer to sell securities or the solicitation of an offer to buy securities in any jurisdiction where such offer or solicitation is not permitted.
Upstream is a MERJ Exchange market. MERJ Exchange is a licensed Securities Exchange, an affiliate of the World Federation of Exchanges, a National Numbering Agency, and a member of ANNA. MERJ is regulated in the Seychelles by the Financial Services Authority, https://fsaseychelles.sc/, an associate member of the International Association of Securities Commissions (IOSCO). MERJ supports global issuers of traditional and digital securities through the entire asset life cycle from issuance to trading, clearing, settlement, and registry. It operates a fair and transparent marketplace in line with international best practices and principles of operations of financial markets. Upstream does not endorse or recommend any public or private securities bought or sold on its app. Upstream does not offer investment advice or recommendations of any kind. All services offered by Upstream are intended for self-directed clients who make their own investment decisions without aid or assistance from Upstream. All customers are subject to the rules and regulations of their jurisdiction. By accessing the site or app, you agree to be bound by its terms of use and privacy policy. Company and security listings on Upstream are only suitable for investors who are familiar with and willing to accept the high risk associated with speculative investments, often in early and development-stage companies. U.S. persons may not deposit, buy, or sell securities on Upstream. There can be no assurance the valuation of any particular company’s securities is accurate or in agreement with the market or industry comparative valuations. Investors must be able to afford market volatility and afford the loss of their investment. Companies listed on Upstream are subject to significant ongoing corporate obligations including, but not limited to disclosure, filings, and notification requirements, as well as compliance with applicable quantitative and qualitative listing standards.
Forward-Looking Statements
This blog contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus and other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.